Civetta Therapeuticsfounded In 2019 And Based In Cambridgemassachusettsis A Biotechnology Company Dedicated To Developing Small Molecule Therapeutics That Target Beta Propeller Domains In Proteinsthese Domains Are Significant In The Context Of Cancer And Other Diseasesthe Company Combines Computational Biology With Drug Discovery To Focus On Previously Inaccessible Biological Targetsaiming To Disrupt Critical Protein Protein Interactions That Contribute To Disease Progressionparticularly In Oncology Civetta S Approach Includes Advanced Computational Modeling And Protein Interaction Mapping To Identify And Validate High Selectivity Targetsthe Company Is Actively Engaged In Preclinical Research And Has A Pipeline Of Small Molecule Inhibitorsincluding A Lead Productan S6K1 Inhibitorcivetta Has Raised $53 Million In Fundingprimarily From Deerfield Managementand Operates From A Biotech Hub That Fosters Collaboration With Leading Academic Institutions
